Back to top

Kymera Therapeutics completes enrollment in BROADEN2 trial

Kymera Therapeutics (KYMR) announced it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 de...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Kymera Therapeutics, Inc. (KYMR)